The B6-hBCMA (TNFRSF17) mouse is a humanized model constructed using gene editing technology, where the mouse BCMA endogenous extracellular domain (aa.1~49) was replaced with the human BCMA extracellular domain (aa.1~54). Homozygous B6-hBCMA (TNFRSF17) mice are viable and fertile. This model can be used for studying the pathological mechanisms and therapeutic approaches of multiple myeloma, systemic lupus erythematosus and various B cell-related diseases and for the development of BCMA-targeted drugs.